Professional Marketing briefs: April 2012

Professional Marketing briefs: April 2012
Professional Marketing briefs: April 2012
GlaxoSmithKline and Daiichi ­Sankyo announced they will  team up to create Japan's largest vaccine company. The joint effort will be a 50-50 partnership, with an initial investment of at least ¥100,000,000 ($1.2 million) in seed money, according to a GSK statement. The two companies will distribute vaccines for HPV, rotavirus and measles rubella, among others.

Columbia Laboratories is reducing its headcount by 10, leaving it with 14 employees. The announcement follows the FDA's rejection of the company's progesterone vaginal 8% gel, intended to reduce the risk of pre-term birth. An approval would have meant a $30 million commercial launch payment from Watson Pharmaceuticals, which has the rights to the gel.

Eli Lilly announced the opening of offices with 200 research and manufacturing jobs to fill at its Kinsale campus in County Cork, Ireland (above). The jobs are part of the company's €330 million ($435 million) investment in a campus currently dedicated to small-molecule manufacturing. The investment will expand the site's footprint so that it could be the launch pad for the pharmaceutical company's biologics pipeline.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.